Genentech‘s experimental oral therapy fenebrutinib has become the first Bruton’s tyrosine kinase (BTK) inhibitor to show positive Phase 3 results in both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS), the company announced. In what Genentech called “unprecedented results,” two late-stage trials testing the therapy in these indications have met their primary […]
The post MS drug fenebrutinib shows ‘unprecedented results’ in trials appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com